Nektar Therapeutics

NKTR Healthcare Biotechnology

Nektar Therapeutics' revenue for fiscal 2025 (year ended December 2025) was $55.2 million, down 43.9% from fiscal 2024. In the quarter to June 2026, revenue fell 9.34%, EPS grew 58.3% and free cash flow fell 65.7%, each against the same quarter a year earlier.

35.78 1.94 −5.14%
Market cap
$1.3B
P/E
0.0×
Fwd P/E
−6.3×
Dividend yield
—
F-score
3/9
Altman Z
−17.07
Beneish M
n/a
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
P/E ratio

+8 more quarters

0.00 0.00 0.00 0.00
P/S ratio
17.22 12.91 31.99 42.27
P/FCF ratio
0.00 0.00 0.00 0.00
P/Operating CF
(22.11) (10.98) (40.18) (30.45)
P/B ratio
12.67 7.94 3.09 2.56
Price to Tangible BV
13.49 8.42 3.12 2.57
EV/Sales
20.93 17.56 30.80 38.94
EV/EBITDA
0.00 0.00 0.00 0.00
EV/Operating CF
(6.91) (4.65) (8.41) (9.09)
EV/FCF
(6.88) (4.65) (8.40) (9.08)
Quick Ratio
4.07 4.59 9.85 9.64
Current Ratio
4.24 4.97 10.21 10.42
Net Debt/EBITDA
8.21 10.30 14.02 14.96
Debt/Assets
0.00% 0.00% 0.00% 0.00%
Debt/Equity
0.00 0.00 0.00 0.00
Asset Turnover
0.21 0.19 0.11 0.08
Operating CF/Net income
1.37 1.80 0.99 1.87
Capex/Depreciation
0.09 0.00 0.01 0.03
Interest Coverage
(5.24) (2.83) (4.92) (5.88)
Research and Development Expense of Revenue
231.15% 136.25% 328.51% 386.23%
Selling, General and Administrative Expense of Revenue
136.30% 51.29% 123.74% 126.00%
Intangible Assets out of Total Assets
0.02 0.00 0.00 0.00
Share Based Compensation of Revenue
26.06% 10.06% 30.89% 33.21%
Graham Net Nets
0.06 0.11 0.23 0.24
Graham Number
0.00 0.00 0.00 0.00
Earnings Yield
(14.00%) (24.12%) (11.70%) (9.60%)
Free Cash Flow Yield
(17.66%) (29.26%) (11.46%) (10.14%)
Revenue per Share
0.62 1.29 0.44 0.31
Operating CF per Share
(2.57) (3.85) (1.79) (2.29)
Capex per Share
(0.01) 0.00 0.00 0.00
Free Cash Flow per Share
(2.58) (3.85) (1.79) (2.30)
Cash per Share
14.26 14.57 22.99 20.70
Shareholders Equity per Share
4.49 5.32 23.29 27.32
Interest Debt per Share
0.00 0.00 0.00 0.00
Book value per Share
4.49 5.32 23.29 27.32
Free Cash Flow
(48.87) (64.98) (44.32) (75.86)
Working Capital
215.02 212.73 531.33 668.42
Capital Expenditures
(0.11) (0.02) (0.02) (0.09)
Net Current Asset Value
65.10 75.69 401.99 547.39
EV/EBIT
0.00 0.00 0.00 0.00
Capex to Sales
0.01 0.00 0.00 0.01
Price to Operating Income
0.00 0.00 0.00 0.00
Other line items
Average Payables
12.07 11.17 13.93 19.59
Average Assets
304.66 292.13 509.76 651.33
Average Common Equity
66.99 75.28 294.98 439.46

Fold the line items

Columns are period end dates